246710.KQ T&R Biofab Co. Ltd
- Market cap
- KRW 86.6B
- P/E
- -
- P/B
- 4.08x
- ROE
- -51.3%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 246710.KQ undervalued?
Graham numberThe Graham number of T&R Biofab Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
T&R Biofab Co. Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-51.3%), below 10%.
ROA 0/1
Return on assets (-11.7%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-88.5%) is below the industry median (1.8%).
Revenue Growth 2/2
Revenue grew 67.3% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (75.7%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (4.1x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
T&R Biofab Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.
Full company profileT&R Biofab Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
T&R Biofab Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 274M | 406M | 974M | 1.29B | 6.81B | 3.23B | 5.75B | 5.20B | 4.87B | 27.0B | 36.5B |
| Gross Profit | 54.1M | 106M | 281M | 609M | 2.66B | -212M | 1.54B | 1.08B | 2.13B | 6.88B | 11.8B |
| Operating Income | -3.10B | -4.16B | -4.93B | -6.86B | -5.51B | -10.4B | -8.04B | -13.5B | -8.77B | -8.57B | -3.67B |
| EBITDA | - | - | - | - | - | - | -8.39B | -11.3B | -2.20B | -20.8B | -4.95B |
| Net Income | -3.02B | -4.06B | -4.69B | -6.25B | -5.60B | -11.1B | -10.3B | -13.4B | -7.68B | -32.0B | -10.9B |
| EPS | -250 | -313 | -288 | -374 | -332 | -536 | -488 | -623 | -356 | -672 | -229 |
| Balance Sheet | |||||||||||
| Total Assets | 9.59B | 9.47B | 31.1B | 27.1B | 48.5B | 82.2B | 75.9B | 99.8B | 98.5B | 92.7B | 92.8B |
| Total Liabilities | 738M | 395M | 837M | 2.33B | 2.45B | 40.5B | 36.7B | 68.6B | 74.2B | 66.6B | 71.6B |
| Shareholders' Equity | 8.85B | 9.07B | 30.3B | 24.8B | 46.1B | 41.7B | 39.3B | 31.2B | 24.2B | 26.1B | 21.2B |
| Cash & Short-term Investments | 8.06B | 7.80B | 28.8B | 21.7B | 36.9B | 58.2B | 40.4B | 51.7B | 17.3B | 7.76B | 6.03B |
| Total Debt | - | - | - | 650M | 498M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.59B | -3.72B | -5.66B | -5.17B | -8.38B | -7.56B | -5.89B | -6.96B | -11.7B | -7.47B | -1.39B |
| Capital Expenditure | 644M | 214M | 452M | 668M | 1.69B | 1.13B | 10.8B | 12.7B | 2.81B | 2.40B | 3.03B |
| Free Cash Flow | - | - | - | - | -10.5B | -16.6B | -16.9B | -19.7B | -14.5B | -9.87B | -4.42B |
| Ratios | |||||||||||
| ROE | -34.1% | -44.7% | -15.5% | -25.2% | -12.2% | -26.6% | -26.3% | -43.0% | -31.7% | -122.6% | -51.3% |
| ROA | -31.5% | -42.9% | -15.1% | -23.1% | -11.6% | -13.5% | -13.6% | -13.4% | -7.8% | -34.5% | -11.7% |
| Net Profit Margin | -1,101.3% | -1,000.7% | -481.7% | -485.7% | -82.4% | -342.6% | -179.6% | -258.1% | -157.6% | -118.5% | -29.8% |
| Debt to Equity | - | - | - | 0.03x | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
T&R Biofab Co. Ltd dividends
T&R Biofab Co. Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1.2:1 on Oct 29, 2025.
Who owns T&R Biofab Co. Ltd
- Insiders 14.92%
- Institutions 5.64%
- Public & others 79.44%
- Shares outstanding 47.6M
- Free float 40.5M
T&R Biofab Co. Ltd company profile
- Company name
- T&R Biofab Co. Ltd
- Ticker
- 246710.KQ
- ISIN
- KR7246710008
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 86
- Fiscal year end
- December
- Address
- 96, Mayu-ro, Siheung-si, South Korea, 15111
- Phone
- 82 3 1431 3344
- Website
- tnrbiofab.com
About T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.
T&R Biofab Co. Ltd management
1- Wonsoo YunCPO, CEO & President